BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11343379)

  • 21. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
    Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
    Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma].
    Xu G; Wang HF; He G; Xie K
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):351-5. PubMed ID: 19799083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2.
    García JF; Piris MA; Lloret E; Orradre JL; Murillo PG; Martínez JC
    Histopathology; 1997 Feb; 30(2):120-5. PubMed ID: 9067734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis.
    King LA; Okagaki T; Gallup DG; Twiggs LB; Messing MJ; Carson LF
    Gynecol Oncol; 1996 May; 61(2):227-32. PubMed ID: 8626138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
    Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
    Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.
    Mathoulin-Portier MP; Viens P; Cowen D; Bertucci F; Houvenaeghel G; Geneix J; Puig B; Bardou VJ; Jacquemier J
    Oncol Rep; 2000; 7(3):675-80. PubMed ID: 10767389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
    Ng IO; Lam KY; Ng M; Regezi JA
    Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
    Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
    Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.
    Stefanaki K; Rontogianni D; Kouvidou CH; Bolioti S; Delides G; Pantelidaki A; Sotsiou F; Kanavaros P
    Histopathology; 1997 Jun; 30(6):549-55. PubMed ID: 9205859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years.
    Regezi JA; Dekker NP; McMillan A; Ramirez-Amador V; Meneses-Garcia A; Ruiz-Godoy Rivera LM; Chrysomali E; Ng IO
    Oral Oncol; 1999 Jul; 35(4):379-83. PubMed ID: 10645402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse.
    Naresh KN; O'Conor GT; Soman CS; Johnson J; Advani SH; Magrath IT; Bhatia KG
    Hum Pathol; 1997 May; 28(5):549-55. PubMed ID: 9158703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors.
    Gustafsson B; Axelsson B; Gustafsson B; Christensson B; Winiarski J
    Pediatr Hematol Oncol; 2001 Dec; 18(8):497-508. PubMed ID: 11764099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200 cases.
    Korkolopoulou P; Patsouris E; Pangalis G; Tsenga A; Elemenoglou J; Thomas-Tsangli E; Spandidos D; Kittas C
    Hum Pathol; 1993 Apr; 24(4):371-7. PubMed ID: 7684020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.